KOLOA, Hawaii — Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here.
During a presentation at Retina 2025, John W. Kitchens, MD, shared highlights from DRCR Retina Network studies across the past 20 years.
“We cannot overstate some of these fundamental contributions to clinical care,” he said.
Combination therapy for diabetic macular edema with an intravitreal dexamethasone implant and an anti-VEGF such as ranibizumab offers an enhanced drying effect on the